Overview

Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Efficacy and safety evaluation of tolvaptan in the treatment of patients with right heart failure caused by pulmonary arterial hypertension
Phase:
N/A
Details
Lead Sponsor:
Chinese Pulmonary Vascular Disease Research Group
Treatments:
Furosemide
Tolvaptan